Previous 10 | Next 10 |
Agile Therapeutics (NASDAQ: AGRX ): Q1 GAAP EPS of -$0.13 misses by $0.03 . More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today rep...
PRINCETON, N.J., March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 a...
PRINCETON, N.J., March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation du...
Agile Therapeutics (NASDAQ: AGRX ): Q4 GAAP EPS of -$0.11 beats by $0.04. Cash and cash equivalents of $7.8M Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J., March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reporte...
PRINCETON, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tu...
Thinly traded nano cap Agile Therapeutics ( AGRX +20.8% ) is up on a 7x surge in volume on the heels of its private placemen t of ~8.4M shares of common stock at $0.93 per share yielding gross proceeds of ~$7.8M. More news on: Agile Therapeutics, Inc., Healthcare stocks news, Stocks on ...
PRINCETON, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC, for the private placement of approximately 8.4 mill...
On February 11 th , Agile Therapeutics ( AGRX ) reported topline results from their comparative wear study challenging the adhesion of Twirla matched against Xulane (Figure 1). Once the news hit the wire, AGRX quickly traded up above $1.00 in the premarket but was quickly hit with selling ...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...